CoChat
Sign Up
Cited by 4

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

ASGR1 is a promising target for lipid reduction in pigs with PON2 as its inhibitor

Yin, Yunjun, Liu, Jun, Yu, Jia, Dong, Dingcai, Gao, Fei, Yu, Libao, Du, Xuguang, Wu, Sen·2024·iScience
DOI 10.1016/j.isci.2024.110288PMC PMC11269292
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.isci.2024.110288

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Pigs lacking ASGR1 showed a decrease in non-HDL cholesterol in the circulation and a reduction in atherosclerotic lesions after a high-fat high-cholesterol diet, with no apparent liver damage.

    “Like in human carriers of ASGR1 inactivating mutations, pigs lacking ASGR1 showed a decrease in non-HDL cholesterol in the circulation and a reduction in atherosclerotic lesions after a high-fat high-cholesterol diet, with no apparent liver damage [85,86].”

    From The low-density lipoprotein receptor: Emerging post-transcriptional regulatory mechanisms (2025) · cites this paper as [86]

    The Results report reduced serum lipids, including non-HDL cholesterol, in ASGR1+/− pigs and no apparent hepatic inflammation or liver damage. But the Methods say the pigs had normal food, and the paper does not report reduced atherosclerotic lesions in ASGR1-deficient pigs after a high-fat, high-cholesterol diet. Its Introduction discusses lesions after a high-fat diet in mice lacking PON2, not these pigs. (LLM, conf=0.90)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 34

  1. 2020, Repositioning of the global epicentre of non-optimal cholesterol, Nature, 582, 73, 10.1038/s41586-020-2338-1 · DOI
  2. Sharpe, 2013, Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), J. Biol. Chem., 288, 18707, 10.1074/jbc.R113.479808 · DOI · Paper page
  3. Tobert, 2003, Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors, Nat. Rev. Drug Discov., 2, 517, 10.1038/nrd1112 · DOI
  4. Ge, 2008, The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1, Cell Metabol., 7, 508, 10.1016/j.cmet.2008.04.001 · DOI
  5. Robinson, 2015, Efficacy and safety of alirocumab in reducing lipids and cardiovascular events, N. Engl. J. Med., 372, 1489, 10.1056/NEJMoa1501031 · DOI · Paper page
  6. Gennemark, 2021, An oral antisense oligonucleotide for PCSK9 inhibition, Sci. Transl. Med., 13, 10.1126/scitranslmed.abe9117 · DOI
  7. German, 2020, Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9, BioDrugs, 34, 1, 10.1007/s40259-019-00399-6 · DOI
  8. Collins, 2016, Interpretation of the evidence for the efficacy and safety of statin therapy, Lancet, 388, 2532, 10.1016/S0140-6736(16)31357-5 · DOI · Paper page
  9. Mu, 2020, Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials, Adv. Ther., 37, 1496, 10.1007/s12325-020-01259-4 · DOI
  10. Geuze, 1983, Intracellular site of asialoglycoprotein receptor-ligand uncoupling: double-label immunoelectron microscopy during receptor-mediated endocytosis, Cell, 32, 277, 10.1016/0092-8674(83)90518-4 · DOI
  11. Stockert, 1995, The asialoglycoprotein receptor: relationships between structure, function, and expression, Physiol. Rev., 75, 591, 10.1152/physrev.1995.75.3.591 · DOI
  12. Morell, 1968, Physical and chemical studies on ceruloplasmin. V. Metabolic studies on sialic acid-free ceruloplasmin in vivo, J. Biol. Chem., 243, 155, 10.1016/S0021-9258(18)99337-3 · DOI
  13. Ashwell, 1982, Carbohydrate-specific receptors of the liver, Annu. Rev. Biochem., 51, 531, 10.1146/annurev.bi.51.070182.002531 · DOI · Paper page
  14. Xie, 2021, Deficiency of ASGR1 in pigs recapitulates reduced risk factor for cardiovascular disease in humans, PLoS Genet., 17, 10.1371/journal.pgen.1009891 · DOI · Paper page
  15. Navab, 2004, The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL, J. Lipid Res., 45, 993, 10.1194/jlr.R400001-JLR200 · DOI
  16. Libby, 2011, Progress and challenges in translating the biology of atherosclerosis, Nature, 473, 317, 10.1038/nature10146 · DOI · Paper page
  17. Sorokin, 2018, Association Between Oxidation-Modified Lipoproteins and Coronary Plaque in Psoriasis, Circ. Res., 123, 1244, 10.1161/CIRCRESAHA.118.313608 · DOI
  18. She, 2012, The human paraoxonase gene cluster as a target in the treatment of atherosclerosis, Antioxidants Redox Signal., 16, 597, 10.1089/ars.2010.3774 · DOI
  19. Durrington, 2001, Paraoxonase and atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 21, 473, 10.1161/01.ATV.21.4.473 · DOI
  20. Ng, 2001, Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein, J. Biol. Chem., 276, 44444, 10.1074/jbc.M105660200 · DOI
  21. Ng, 2006, Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2, J. Biol. Chem., 281, 29491, 10.1074/jbc.M605379200 · DOI
  22. Ng, 2006, Adenovirus mediated expression of human paraoxonase 2 protects against the development of atherosclerosis in apolipoprotein E-deficient mice, Mol. Genet. Metabol., 89, 368, 10.1016/j.ymgme.2006.07.004 · DOI
  23. Feng, 2020, Measuring targeting specificity of genome-editing by nuclear transfer and sequencing (NT-seq), Cell Discov., 6, 78, 10.1038/s41421-020-00205-6 · DOI
  24. Herzig, 2018, AMPK: guardian of metabolism and mitochondrial homeostasis, Nat. Rev. Mol. Cell Biol., 19, 121, 10.1038/nrm.2017.95 · DOI
  25. Shao, 2016, The roles of macrophage autophagy in atherosclerosis, Acta Pharmacol. Sin., 37, 150, 10.1038/aps.2015.87 · DOI
  26. Li, 2011, AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice, Cell Metabol., 13, 376, 10.1016/j.cmet.2011.03.009 · DOI
  27. Gallagher, 2013, Early signalling events of autophagy, Essays Biochem., 55, 1
  28. Abada, 2014, Getting ready for building: signaling and autophagosome biogenesis, EMBO Rep., 15, 839, 10.15252/embr.201439076 · DOI
  29. Luck, 2020, A reference map of the human binary protein interactome, Nature, 580, 402, 10.1038/s41586-020-2188-x · DOI · Paper page
  30. Xu, 2017, piggyBac mediates efficient in vivo CRISPR library screening for tumorigenesis in mice, Proc. Natl. Acad. Sci. USA, 114, 722, 10.1073/pnas.1615735114 · DOI
  31. Lu, 2021, A HIT-trapping strategy for rapid generation of reversible and conditional alleles using a universal donor, Genome Res., 31, 900, 10.1101/gr.271312.120 · DOI
  32. Bae, 2014, Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases, Bioinformatics, 30, 1473, 10.1093/bioinformatics/btu048 · DOI · Paper page
  33. Liu, 1999, Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA, Gene Ther., 6, 1258, 10.1038/sj.gt.3300947 · DOI
  34. Sánchez-Rivera, 2014, Rapid modelling of cooperating genetic events in cancer through somatic genome editing, Nature, 516, 428, 10.1038/nature13906 · DOI

Cited by

Sorted by citations

Metadata

Authors
Yin, Y., Liu, J., Yu, J., Dong, D., Gao, F., Yu, L., Du, X., & Wu, S.
ORCID
Wu, Sen
Venue
iScience
Publisher
Elsevier BV
Published
2024-07
Volume
27
Issue
7
Pages
110288
ISSN
2589-0042
DOI
10.1016/j.isci.2024.110288
PMC
PMC11269292
Cited by
4
References
8
Language
en
Licence
Funders
  • Higher Education Discipline Innovation Project (B12008)
  • National Natural Science Foundation of China (32002180, 32172715)
  • National Key Research and Development Program of China (202002011, 2021YFA0805901, 2021YFA0805900)
  • Sanya Yazhou Bay Science and Technology City
  • Key Research and Development Project of Hainan Province (ZDYF2021SHFZ230)
  • Ministry of Education of the People's Republic of China

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review